Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

R&D Reprioritization Eliminates Most Gene Therapy Programs

Sarepta laid off 500 people but promoted others in the C-suite, giving the execs raises (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business